05 April 2022

تحذيرات و تعاميم

Reference: CIR-2022-00000074

To all Health facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circular issued by the MOHAP for perusal and adhere to what is stated

 

Medical Device Lots Recall Covidien DAR™ airway products

 

Affected Lots of Covidien DAR™ airway products

 

Notification of Discrepancy in the Arabic Section of Product Information Leaflet REXULTI ® (REX-ul-TE) (brexpiprazole) Tablets

 

Lifting the Suspension on the Registration & Marketing of the Product Julmentin 156mg/5ml Oral Suspension

 

Safety update for TNF blockers - Simponi ® (Golimumab)

 

Voluntary Recall of a Pharmaceutical product Maxiflam Soft Gelatin Capsule (Ibuprofen 200 mg and Paracetamol 500 mg)

 

 

Lifting the Suspension of Pharmaceutical Product JUSPRIN 81mg

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

تقارير السلامة للوسائل الطبية - سحب تشغيلات - Covidien DAR-1 (1).pdf:

View Document

UAE.xlsx:

View Document

- النشرة الداخلية للمنتج الطبي - REXULTI.pdf:

View Document

رفع التعليق عن تسجيل وتسويق المنتج الطبي - Julmentin 156mg.pdf:

View Document

اضافة تحذير - Simponi.pdf:

View Document

سحب طوعي للمستحضر الصيدلاني - Maxiflam.pdf:

View Document

رفع تعليق تسجيل عن المنتج الطبي - Jusprin - Julphar.pdf:

View Document